Pacira Biosciences (NASDAQ:PCRX) posted its earnings results on Thursday. The company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.35, Briefing.com reports. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The company had revenue of $104.69 million for the quarter, compared to analysts’ expectations of $104.88 million. During the same quarter in the prior year, the company posted $0.31 earnings per share. Pacira Biosciences’s revenue for the quarter was up 25.5% compared to the same quarter last year.
NASDAQ:PCRX traded up $1.40 on Friday, reaching $44.02. 711,200 shares of the company’s stock were exchanged, compared to its average volume of 631,161. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 151.79, a price-to-earnings-growth ratio of 1.96 and a beta of 1.13. Pacira Biosciences has a 52-week low of $34.64 and a 52-week high of $50.90. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99. The business has a fifty day moving average of $39.20 and a 200-day moving average of $41.12.
A number of research firms have commented on PCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price on shares of Pacira Biosciences in a research report on Thursday. Zacks Investment Research raised shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 target price on the stock in a research report on Friday, August 2nd. BTIG Research assumed coverage on shares of Pacira Biosciences in a research report on Wednesday. They issued a “buy” rating and a $56.00 target price on the stock. Jefferies Financial Group set a $60.00 price target on shares of Pacira Biosciences and gave the stock a “buy” rating in a research note on Tuesday, October 8th. Finally, BMO Capital Markets cut their price target on shares of Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating on the stock in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $52.55.
In other news, CEO David M. Stack sold 12,849 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $39.15, for a total value of $503,038.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kristen Marie Williams sold 6,252 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total value of $246,891.48. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company’s stock.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Featured Story: Outstanding Shares
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.